GENERAL INFORMATION

Accommodations

Accommodations for the conference are at the Aldemar Olympia Hotel.  The hotel is located in town of Skafidia, 332 km from Athens International Airport.

Arrival and Check-in 

It is expected that attendees will arrive/check-in on Friday after 2:00 PM. Anyone arriving after 11:00 pm on Sunday must make alternative dinner arrangements. 

Airport Shuttle

There will be airport shuttles from Athens International Airport (ATH) to the Aldemar Royal Olympia Conference Center & Hotel free of charge on June 6, 2014 and return back to Athens International Airport (ATH) on June 11, 2014

Conference Venue

The Aldemar Conference Center is located at the hotel.  

Handicapped Accessibility 

The site is fully handicapped accessible. 

Posters

Posters should be mounted Saturday, June 7 between 7:45 – 10:45 AM, on the designated boards and dismounted at the closing of the conference. The dimensions of the boards are 90 cm wide X 120 cm high. Adhesive tape for mounting the posters on the boards will be available at the poster area.

Oral Presentations

Speakers are asked to bring their USB flash drive to the reception desk at least 30 minutes prior to the session.  The allocated time for all presentations, unless otherwise indicated, includes five minutes Q&A.

Olympia Tour

Buses for the Olympia tour will depart from the hotel front lobby on Monday, June 9 at 3:30 pm. Badges are required for participation.

Breakfast

Breakfast for registered participants and registered accompanying persons will be served at the Aldemar Hotel main restaurant during the hours scheduled in this program.

Lunches/Informal Discussions

Lunches for registered participants and registered accompanying persons will be served during the times indicated in this program at the main restaurant. Badges are required for admission.

Dinners/Informal Discussions

Three of the dinners/informal discussion will be served during the times indicated in the program. Vegetarian entrees are available only upon request in advance of the meeting.  Please contact info@aegeanconferences.org. 

Internet, Phone, & Computer 

Wireless Internet access is located throughout the conference center free of charge during meeting hours. There are computers available in the hotel’s business center for the use of the attendees. Phone service is available for an additional charge from your hotel room. 

Certificate of Participation

A Certificate of Participation will be distributed to a participant for those sessions that the participant has attended. A participant must attend an entire session to receive credit for that particular session. Late arrivals and early departures from a session will preclude a participant from receiving credit for that session.

Other Information

Animals are not permitted on site. 

Badges are required for admission to all events. 

All Aegean Conferences events are non-smoking. 

No Photographs and Recording Devices 

Participants are not allowed to photograph and/or record using cameras, mobile telephones and other recording devices during the slide and poster presentations.

Friday, June 06

6:00-8:00

Conference Registration at Hotel Lobby

8:00 PM

Welcome Reception/Dinner

Saturday, June 07

7:30 AM

Breakfast

8:15 AM

Welcome & Opening Remarks

John D Lambris

Keynote Presentation

8:30 AM

1

US National Institutes of Health (NIH) Funding for Immunology Research

Helen Quill

Session I

Cancer Biology & Therapy

Chairs: Ghebrehiwet, Pio

8:55 AM

2

GC1qR is an important contributor to tumor growth and metastasis

Berhane Ghebrehiwet, Yan Ji, Alisa Valentino, and Ellinor IB Peerschke

9:20 AM

3

Role of complement activation in lung cancer growth

Ruben Pio

9:45 AM

4

Cytotoxic Mechanisms of Immunotherapy: Harnessing Complement in the Action of Anti-tumor Monoclonal Antibodies

Ronald P Taylor, Margaret A Lindorfer, Frank J Beurskens, and Paul WHI Parren

10:10 AM

5

Radiotherapy-induced complement activation supports tumor-specific immunity and is crucial to therapeutic efficacy

Laura Surace, Veronika Lysenko, Antonela Bivcic, Andrea Orlando Fontana, Virginia Cecconi, Martin Pruschy, Michal Okoniewsky, Reinhard Dummer, and Maries van den Broek

10:25 AM

6

A new pan-specific assay for measuring Complement Activation in Animals: Validation in vitro and in vivo, in the rat and pig models of complement activation-related pseudoallergy 

János Szebeni, Tamás Mészáros, Rudolf Urbanics, László Dézsi, Tamás Fülöp, László Rosivall and Marieluise Wippermann

10:40 AM

7

Distinct roles of properdin in murine models of intestinal inflammation

Umang Jain, Wilhelm J Schwaeble, Cordula M Stover, and Andrew W Stadnyk

10:55 AM

Coffee Break & Poster Viewing

Session II

Transplantation & Thromboinflammation

Chairs: Nilsson, Nicolls

11:30 AM

8

Controlling complement activation in xenotransplantation

Peter J Cowan

11:55 AM

9

The Role of Complement in Transplant Microvascular Disease

Mohammed A Khan and Mark Nicolls

12:20 PM

10

Targeted inhibition of complement delays the onset of antibody-mediated rejection in a mouse heterotopic heart transplant model

Carl Atkinson, Martin Goddard, and Stephen Tomlinson

12:35 PM

11

Therapeutic strategies to control complement-mediated thrombus formation and fetal loss in antiphospholipid syndrome

Chiara Agostinis, Paolo Durigutto, Daniele Sblattero, Maria O Borghi, Roberta Bulla, Pier Luigi  Meroni, and Francesco Tedesco

1:00 PM

12

The lectin pathway is the crossroad between complement and coagulation in thromboinflammation

Bo Nilsson

1:25 PM

13

Contact activation of C3 enables tethering between activated platelets and polymorphonuclear leukocytes via CD11b/CD18

Kristina N Ekdahl

1:50 PM

14

Anaphylatoxinreceptor C3aR on platelets contributes to arterial thrombosis - intersection between innate immunity and thrombosis

Manuela Sauter, RJ Sauter, R Schleicher, B Krämer, O Borst, M Gawaz, P Kraft, C Kleinschnitz, JD Lambris, and HF Langer

2:05 PM

Lunch / Informal Discussions

7:30 PM

Dinner / Informal Discussions at a local Greek Taverna

Buses depart from the hotel lobby at 7:30 PM

Sunday, June 08

7:30 AM

Breakfast

Session III

Hematological & Metabolic Disorders

Chairs: Blom, Risitano

8:30 AM

15

Unmet clinical needs in paroxysmal nocturnal hemoglobinuria: how far we are from second-generation complement inhibitors?

Antonio M Risitano, Patrizia Ricci, Simona Pagliuca, Serena Marotta, Zhuoer Lin, Christoph Q Schmidt, Despina Yancopoulou, Daniel Ricklin, and John D Lambris

8:55 AM

16

Genetic Variants in C5 Confers Poor Response to the Anti-C5 Monoclonal Antibody Eculizumab

Jun-ichi Nishimura

9:20 AM

17

Invariant T cells in allo- and auto-reactivity

Anastasios Karadimitris

9:45 AM

18

TNT009, a First-in-Class Anti-C1s Antibody, Prevents Classical Pathway Activation in Autoantibody-Mediated Diseases

Nancy Stagliano, Ju Shi, Eileen Rose, Sami Hussain, Andrew Singh, Graham Parry, and Sandip Panicker

10:00 AM

19

The complement system in metabolic disease

Julia Phieler, Antonios  Chatzigeorgiou, Kyoung-Jin Chung, John Lambris, and Triantafyllos Chavakis

10:25 AM

20

The complement inhibitor CD59 regulates insulin secretion by modulating exocytotic events

Anna M Ulrika Krus, Ben C King, Vini Nagaraj, Nikhil R Gandasi, Jonatan Sjölander, Pawel Buda, Eliana Garcia-Vaz, Maria F Gomez , Emilia Ottosson–Laakso, Petter Storm, Malin Fex, Petter Vikman, Enming Zhang, Sebastian Barg, Erik Renström, and Anna M Blom

10:50 AM

Coffee Break & Poster Viewing

Session IV

Targets & Inhibitors: Inititiation/Amplification

Chairs: Garred, Gal

11:50 AM

21

Regulation of complement activation by chimeric molecules 

Lea Munthe-Fog, , Mie Anemone  Nordmaj, , Mikkel Ole Skjoedt, and Peter Garred

12:15 PM

22

Peptide inhibitor of complement C1 (PIC1), a novel suppressor of classical pathway activation: mechanistic studies and clinical potential

Neel K Krishna, and Kenji M Cunnion

12:40 PM

23

SOMAmer Inhibitors of the Complement System

Daniel W Drolet, Chi Zhang, Daniel J O’Connell, Shashi Gupta, and Nebojsa Janjic

12:55 PM

24

Dimerization and heterodimer formation properties of MASPs, proteases of the complement lectin pathway

Jozsef Dobo, Katalin Paréj, Ágnes Hermann, Nóra Donáth, Péter Závodszky, and Péter  Gál

1:10 PM

25

TBA 

Wilhelm J Schwaeble 

1:35 PM

26

Controlling C3 activation in solution and on the cell surface: recent progress in the preclinical development of compstatin, mini-FH and FH-binding peptides

Daniel Ricklin

2:00 PM

Lunch / Informal Discussions

7:30 PM

Dinner / Informal Discussions at a local Greek Taverna

Buses depart from the hotel lobby at 7:30 PM

Monday, June 09

7:30 AM

Breakfast

Session V

Targets & Inhibitors: Terminal Pathway

Chairs: Andersen, Woodruff

8:30 AM

27

The mechanism of complement inhibitors explained through structural studies

Gregers R Andersen and Yatime Laure

8:55 AM

28

TBA Bedrosian

Camille Bedrosian

9:20 AM

29

Pharmacological inhibition of the complement C5a receptor (C5aR) protects against dopamine neuron degeneration in experimental Parkinson’s disease

Trent M Woodruff, S Mantavani, K Zhou, A Garin-Michaud, AG Kanthasamy, and R Gordon

9:45 AM

30

Introducing SOBI002, a small Affibody-ABD fusion protein targeting complement component C5  

Patrik Strömberg

10:00 AM

31

Phase I Clinical Trial of Coversin, a Novel Complement C5 and LTB4 Inhibitor

Wynne H Weston-Davies, John-Paul Westwood, Miles Nunn, Samuel J Machin, Ian J Mackie, Andrew Chitolie, and Raymond Prudo

10:15 AM

32

siRNA-Mediated C5 Silencing for Complement Inhibition

Anna Borodovsky, Kristina Yucius, Andrew Sprague, James Butler, Shannon Fishman, Tuyen Nguyen, Akshay Viashnaw, Martin Maier, Rajeev Kallanthottathil, Satya Kuchimanchi, Muthiah Manoharan, Rathel Meyers, Kevin Fitzgerald, and Benny Sorensen

10:30 AM

Coffee Break & Poster Viewing

Session VI

Eye & Kidney Disorders

Chairs: Atkinson, Smith

11:15 AM

33

Rare Variants in the Alternative Pathway of Complement (APC) in Age-Related Macular Degeneration (AMD)

John P Atkinson, Elizabeth Schramm, Michael Triebwasser, David Kavanagh, Yi Yu, Soumya Raychandhuri, and Johanna Seddon

11:40 AM

34

Complement factor H is as effective as anti-VEGF against choroidal neovascularization in a rat model of neovascular AMD

Virginie Dinet, Mohamed El Sanharawi, Sylvie Jorieux, Toufik Abache, Kimberley Delaunay, Marie-Christine Naud, Rémi Urbain, Francine Behar-Cohen, and Frédéric Mascarelli

11:55 AM

35

Regulators of complement activity act as scavengers of malondialdehyde adducts – a novel role for C4b-binding protein.

Nikolina Papac Milicevic, Frida C Mohlin, David Weismann, Clara J Busch, Barbara Bartolini Gritti, Anna M Blom, and Christoph J Binder

12:10 PM

36

Age related maculopathy susceptibility protein 2 (ARMS2) binds to apoptotic cells and recruits properdin to enhance opsonization 

Sven Micklisch, Marcus Karlstetter, Lisa Schmölz, Hans-Martin  Dahse, Yuchen Lin, Bernhard HW  Weber,  Stefan Lorkowski, Thomas Langmann, Peter F Zipfel, and Christine Skerka

12:25 PM

37

Soluble CR1 Therapy Improves Complement Regulation in C3 Glomerulopathy

Richard JH Smith, Xue Xiao, Carla M Nester, Danniele G Holanda, Henry C Marsh, Nicole C Meyer, Sanjeev Sethi, and Yuzhou Zhang

12:50 PM

38

CFHR Copy Number Variations in the CFHR (Complement Factor H Related) Gene Cluster in Patients with C3G with DDD 

Peter F Zipfel, Qian Chen, and Christine Skerka

1:15 PM

39

Factor H-related protein 5 (CFHR5) interacts with pentraxin 3 and the extracellular matrix and modulates complement activation

Anne Kopp, Ádám I. Csincsi, Miklós Zöldi, Zsófia Bánlaki, Barbara Uzonyi, and Mihály Józsi

1:30 PM

Lunch / Informal Discussions

3:00 PM

Sightseeing and a guided  tour of Ancient Olympia

7:30 PM

Dinner / Informal Discussions at a local Greek Taverna

Dinner to follow the tour. Buses do not return prior to dinner

Tuesday, June 10

7:30 AM

Breakfast

Session VII

Host-Pathogen Interaction & Infectious Diseases

Chairs: Geisbrecht, Hajishengallis

9:00 AM

40

C3 as a therapeutic target in periodontal dysbiosis and inflammation

George Hajishengallis, Tomoki Maekawa, Toshiharu Abe, Evlambia Hajishengallis, Robert A DeAngelis, Daniel Ricklin, and John D Lambris

9:25 AM

41

Treponema denticola, complement and periodontal disease: The paradox of Factor H cleavage

Richard T Marconi, and Daniel P Miller

9:50 AM

42

Selective Inhibition of Complement and Neutrophil Serine Protease Activity by a Family of Secreted Staphylococcal Immune Evasion Proteins

Brian V Geisbrecht, Daphne AC Stapels, Kasra X Ramyar, Jordan L Woehl, Daniel Ricklin, John D Lambris, and Suzan HM Rooijakkers

10:15 AM

43

Pathogens and complement – regulator hijack, pathway manipulation and the ambiguous CFHRs

Susan M Lea

10:40 AM

Coffee Break & Poster Viewing

Session VIII

Trauma, Inflammation & Sepsis

Chairs: Holers, Huber-Lang

11:40 AM

44

Multiple Recognition and Amplification Mechanisms Underlie Complement-Mediated Damage in the Collagen Antibody-Induced Arthritis Model of Rheumatoid Arthritis

Nirmal Banda, Liudmila Kulik, Steffen Thiel, and Michael V Holers

12:05 PM

45

Role of Complement in Trauma-Hemorrhage 

Markus S Huber-Lang, Stephanie  Denk, Sebastian Weckbach, Rolf Brenner , John D Lambris, and Martijn van Griensven

12:30 PM

46

C5a-dependent acute lung injury involves the release of extracellular histones

Markus Bosmann, Robert Ruemmler, Norman F.  Russkamp, Jamison J. Grailer, Firas S. Zetoune, and Peter A. Ward

12:45 PM

47

Inhibition of mannose binding lectin is protective in experimental traumatic brain injury

Maria-Grazia De Simoni, Daiana De Blasio, Franca Orsini, Stefano Fumagalli , Luca Longhi, Alessandro Palmiori, Matteo Stravalaci, Marco Gobbi, and Anna Bernardi

1:00 PM

48

Septic Cardiomyopathy: Linkage between Complement and TLRs

Peter A Ward, Jamison J Grailer, Miriam Kalbitz, Fatemeh Fattahi, and Firas Zetoune

1:25 PM

49

Double-blockade of CD14 and complement C5 abolishes the cytokine storm and improves morbidity and survival in polymicrobial sepsis in mice

Markus Huber-Lang, Andreas Barratt-Due , Søren E Pischke, Øystein Sandanger, Per H Nilsson, Miles A Nunn, Stephanie Denk, Wilhelm Gaus, Terje Espevik, and Tom E Mollnes

1:40 PM

50

C5a-neutralizing Spiegelmer® NOX-D20 improves outcomes in experimental sepsis

Kai Hoehlig, Nelli Shushakova, Christian Maasch, Klaus Buchner, Werner G Purschke, Dirk Zboralski, Markus Huber-Lang, Axel Vater, and Sven Klussmann

2:05 PM

Lunch / Informal Discussions

8:00 PM

Farewell Dinner

Wednesday, June 11

7:30 AM

Breakfast

Departure

POSTERS

51

The C3-binding domain of staphylococcal extracellular fibrinogen-binding protein (Efb-C) affects interaction of C3b with factor H-related protein 4 and inhibits C3 convertase formation

Ádám I Csincsi, Brian V Geisbrecht, and Mihály Józsi

52

Factor H inhibits liposomal and micellar drug-induced complement activation

Tamás Mészáros, Ádám I. Csincsi, Tamás Fülöp, Barbara Uzonyi, János Szebeni, and Mihály Józsi

53

Structural studies of complement factor 5a receptor – C5aR

Janus Asbjørn Schatz-Jakobsen, Francesca Magnani, Andreas Klos, and Gregers Rom Andersen

54

Polymicrobial Sepsis: Critical Role for C6

Firas S Zetoune, Jamison J Grailer, Fatemeh Fattahi, and Peter A Ward

55

Mannose-binding lectin deficiency protects against vascular dysfunction after transient brain ischemia

Franca Orsini, Ádám Dénes, Stefano Fumagalli, Daiana De Blasio, Eszter Csaszar, and Maria-Grazia De Simoni

56

Structural basis for the inhibition of complement C5a by an L-RNA aptamer

Laure Yatime, Christian Maasch, Kai Hoehlig, Sven Klussmann, Axel Vater, and Gregers Rom Andersen

57

Effects of the compstatin analog Cp40 and of the recombinant mini-Factor H in an in vitro model of isoagglutinin-mediated hemolysis

Patrizia Ricci, Daniel Ricklin, Zhuoer Lin, Christoph Q Schmidt, Michela Sica, John D Lambris, and Antonio M Risitano

58

Complement activation reflects disease severity in Plasmodium falciparum malaria

Per H Nilsson, Aase Berg, Kari Otterdal, Sam Patel, Miguel Gonca, Catarina David, Thor Ueland, Pal Aukrust, Nina Langeland, and Tom Eirik Mollnes

59

In vitro evaluation of monoclonal antibodies in a Human Complement Activation Assay for the pre-clinical Risk Assessment of Anaphylatoxins-release and related first infusion and CARPA reactions

Corinne Ploix, Sabine Bader, Antonio Iglesias, and Thomas Weiser

60

Chemical anti-microbial versus natural products against some oral bacteria, Part I

Surena Vahabi